Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Eton Pharmaceuticals (ETON) EPS (Basic) (2019 - 2025)

Eton Pharmaceuticals (ETON) has disclosed EPS (Basic) for 7 consecutive years, with $0.06 as the latest value for Q4 2025.

  • Quarterly EPS (Basic) rose 300.0% to $0.06 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$0.17 through Dec 2025, down 6.25% year-over-year, with the annual reading at -$0.17 for FY2025, 13.33% down from the prior year.
  • EPS (Basic) hit $0.06 in Q4 2025 for Eton Pharmaceuticals, up from -$0.07 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $0.21 in Q1 2021 to a low of -$210.0 in Q1 2022.
  • Historically, EPS (Basic) has averaged -$10.53 across 5 years, with a median of -$0.06 in 2022.
  • Biggest five-year swings in EPS (Basic): plummeted 100100.0% in 2022 and later surged 400.0% in 2023.
  • Year by year, EPS (Basic) stood at $0.04 in 2021, then grew by 0.0% to $0.04 in 2022, then plummeted by 325.0% to -$0.09 in 2023, then soared by 66.67% to -$0.03 in 2024, then skyrocketed by 300.0% to $0.06 in 2025.
  • Business Quant data shows EPS (Basic) for ETON at $0.06 in Q4 2025, -$0.07 in Q3 2025, and -$0.1 in Q2 2025.